La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Regional Health Props a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Regional Health Props..

Regional Health Props (OTC:RHEPB) Azioni, Catena delle Opzioni

Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.

REGIONAL HLTH PPTY B PFD by Regional Health Properties, Inc.

Regional Health Properties Inc

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 26.75% since its last report. The company recently reported that it has 954 thousand shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065633_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Molina Healthcare Gaining or Losing Market Support?

In the current session, the stock is trading at $34.93, after a 4.75% spike. Over the past month, Lincoln National Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) stock increased by 15.52%, and in the past year, by 17.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747065630_0.png" alt="Past Year Chart" />

<h3>Lincoln National P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Lincoln National has a lower P/E than the aggregate P/E of 14.87 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747065631_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

Price Over Earnings Overview: Lincoln National

Churchill Downs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NYSE">CHDN</a>) short percent of float has fallen 4.17% since its last report. The company recently reported that it has 1.67 million shares sold short, which is 2.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Churchill Downs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Churchill Downs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Churchill Downs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Churchill Downs's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CHDN

How Is The Market Feeling About Churchill Downs?

Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>) has outperformed the market over the past 20 years by 6.36% on an annualized basis producing an average annual return of 14.57%. Currently, Reliance has a market capitalization of $15.67 billion. 
Buying $1000 In RS: If an investor had bought $1000 of RS stock 20 years ago, it would be worth $15,094.99 today based on a price of $296.32 for RS at the time of writing.
<h3>Reliance's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065625_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Did you ever think Grant Cardone, the real estate and business magnate, would <a href="https://www.tiktok.com/@grantcardone/video/7501545634227309867?lang=en">show off his abs</a> in the middle of an interview? That's exactly what happened in a recent TikTok video where he explained how it's easier than people think to become a millionaire.
"You have a better chance of being a millionaire in America than having abs," he proclaimed.&nbsp;
He proceeded to state that there are seven times more people who are millionaires than who have visible abs. Whether you want to be a millionaire, have visible ads, or both, you can achieve meaningful long-term goals with the right approach.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Go All-In</h2>
"The 10X Rule" helped catapult Cardone into the spotlight. In that book, he encourages readers to go all-in with their goals. It's easy to show interest or have a good week, but you need a long-term commitment toward your goals.
Cardone also suggests dominating multiple areas of your life instead of only chasing money. He cares about his family, fitness, and businesses. His life wouldn't be as fulfilling if he only prioritized one of those areas.
Having goals in multiple areas of your life can also make you less prone to distractions. If you have a full calendar that allows you to strengthen yourself in multiple areas, you won't have time for vices or unproductive activities.&nbsp;&nbsp;
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Increase Your Activity</h2>
Cardone isn't a believer in lowering targets to adjust to current circumstances. Instead, he advocates for increasing your activity to make the target more attainable. If you feel like you're falling short on your financial and fitness goals, don't lower them to feel better about your progress. Instead, you review your schedule and look for ways to minimize distractions and be more productive.
"Any target attacked with the right amount of effort within the right amount of time is achievable," Cardone states in his book, "The 10X Rule."
This approach allows you to play offense instead of defense. If you increase your activity, you will likely move closer to your goals. It's better to apply more effort than it is to lower a target. Furthermore, if you lower a target due to thinking it's out of reach, you can fall into that habit moving forward.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Set 10X Goals</h2>
You'll have to work hard throughout your life, but it can be more motivating to work toward a 10X Goal. That's the assertion Cardone makes in his book, and you can apply it to any part of your life. For instance, someone who wants to lose weight can set a goal like having visible abs. That's a more rewarding goal, if achieved, and it can motivate the individual to exercise more often.
On the financial front, aiming for a $5 million net worth may motivate you to put in more effort than striving to have a six-figure net worth. The reward is better if you continue working and learning new skills. You will also have to think of better solutions to current obstacles if you set more ambitious goals.&nbsp;
It's possible to have visible ads, become a millionaire, and achieve both in your life with the right mindset. Embracing the 10X mentality can assist you with any goal.
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

You Have A Better Chance Of Being A Millionaire In America Than Having Abs,' Grant Cardone States While Showing Off That He Has Both

Walt Disney's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) short percent of float has fallen 5.56% since its last report. The company recently reported that it has 21.44 million shares sold short, which is 1.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Walt Disney Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Walt Disney has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Walt Disney's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Walt Disney's peer group average for short interest as a percentage of float is 8.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Walt Disney?

RBC Capital analyst Maurice Choy maintains Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Outperform and lowers the price target from C$65 to C$62.

Price Target

Analyst Ratings

TSX:PPL

RBC Capital Maintains Outperform on Pembina Pipeline, Lowers Price Target to C$62

Compass Point analyst Ed Engel upgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Sell to Neutral.

Upgrades

COIN

Compass Point Upgrades Coinbase Global to Neutral

WIIM

INHD

INNO HOLDINGS shares are trading higher after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.

RBC Capital analyst Andrew Wong maintains Nutrien (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NTR#TSX">NTR</a>) with a Outperform and raises the price target from C$60 to C$65.

TSX:NTR

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to C$65

RBC Capital analyst Andrew Wong maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Outperform and raises the price target from $60 to $65.

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to $65

RBC Capital analyst Maurice Choy reiterates Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Outperform and maintains C$67 price target.

Reiteration

TSX:ENB

RBC Capital Reiterates Outperform on Enbridge, Maintains C$67 Price Target

RBC Capital analyst Maurice Choy reiterates Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) with a Outperform and maintains $67 price target.

RBC Capital Reiterates Outperform on Enbridge, Maintains $67 Price Target

Lantronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) reported in-line earnings for the third quarter, <a href="https://www.benzinga.com/quote/LTRX/earnings">after the closing bell on Thursday</a>.
The company posted quarterly earnings of 3 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $28.50 million which missed the analyst consensus estimate of $29.12 million.
&#8220;We&#8217;re positioning Lantronix to lead the next wave of industrial and enterprise transformation at the edge,&#8221; said Saleel Awsare, president and CEO of Lantronix. &#8220;This quarter reflects continued investment in high-growth areas — from AI-enabled gateways to 5G connectivity — while advancing our innovation roadmap, global partnerships and talent base.&#8221;
Lantronix said it sees fourth-quarter adjusted EPS of $0.00-$0.02, versus market estimates of $0.05 Est, and expects sales of $26.50 million-$30.580 million versus expectations of $30.13 million.
Lantronix shares fell 1.4% to trade at $2.07 on Monday.
These analysts made changes to their price targets on Lantronix following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Ryan Koontz maintained Lantronix with a Buy and lowered the price target from $5.5 to $4.5.</li>
<li>Canaccord Genuity analyst George Gianarikas maintained the stock with a Buy and lowered the price target from $4.5 to $3.</li>
</ul>
Considering buying LTRX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png" alt="" class="wp-image-912121" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

LTRX

These Analysts Cut Their Forecasts On Lantronix Following Q3 Results

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg" alt="" class="wp-image-12776" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Pharma Panic That Could Pay Us</h2>
Executive orders often move markets before move policy is implemented.&nbsp;Late Sunday, President Trump said he'll sign a Most‑Favored‑Nation (MFN) order forcing U.S. payers to match the&nbsp;lowest&nbsp;price any country gets for each prescription drug. Asian investors heard that and immediately slammed Japanese pharma stocks 5‑7 %. If the pattern holds, U.S.‑listed drug makers will open in the red when Wall Street rings the bell.
My read:&nbsp;a&nbsp;knee‑jerk sell‑off would be a gift. The MFN idea died in the courts four years ago and may take months to resurface in enforceable form. Meanwhile, global manufacturers have an obvious counter‑move: pull supply from the handful of ultra‑cheap markets (looking at you, Czech Republic) and re‑launch everywhere at a single, slightly discounted list price. Net revenue changes little; headline risk does all the damage.
Below are the two ways I plan to monetize that dislocation.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;A – Platform Cash&nbsp;Machine With Royalty Armor</h3>
<ul class="wp-block-list">
<li>Fundamentals 
<ul class="wp-block-list">
<li>Piotroski F‑Score&nbsp;9 / 9&nbsp;– pristine balance sheet, rising margins, no accounting red flags.</li>
<li>FY‑24 royalty revenue&nbsp;+27 %&nbsp;y/y; operating cash‑flow margin&nbsp;45 %.</li>
<li>Net debt:&nbsp;$‑170 M&nbsp;(yes, net cash) after another quarter of buybacks.</li>
</ul>
</li>
<li>Technicals 
<ul class="wp-block-list">
<li>Price has stair‑stepped higher since October.&nbsp;</li>
<li>Price is above both 50 and 200 day moving averages&nbsp;– a textbook rising channel.</li>
</ul>
</li>
<li>Why MFN risk is minimal 
<ul class="wp-block-list">
<li>Company&nbsp;A doesn't set list prices; its drug‑delivery platform earns a&nbsp;mid‑single‑digit royalty on&nbsp;net&nbsp;sales&nbsp;paid by its partners.</li>
<li>Those partners are market behemoths—Johnson &amp; Johnson, Inc. (JNJ), Bristol Myers Squibb Company (BMY), Pfizer, Inc. (PFE)—that can afford to yank products from low‑margin jurisdictions until pricing equilibrates.</li>
</ul>
</li>
<li>How I'm playing it 
<ul class="wp-block-list">
<li>Bull‑put credit spread: Taking advantage of expensive puts to collect a net credit which we&#8217;ll get to keep if the stock doesn&#8217;t fall further over the next few months.</li>
<li>Equity kicker: Allocate part of that credit to Jan&nbsp;2026&nbsp;OTM calls. Theta from the spread finances the lottery ticket.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;B – The Diabetes Moon‑Shot</h3>
This one is a pure speculative bet—but with asymmetric payoff.
<ul class="wp-block-list">
<li>Catalyst 
<ul class="wp-block-list">
<li>First‑in‑human trial just made its debut participant&nbsp;insulin‑independent after 30&nbsp;years of Type‑1 Diabetes. Not only doesn&#8217;t he need to take insulin, but he doesn&#8217;t need to take any immunosuppressant drugs either. No safety issues so far.&nbsp;</li>
</ul>
</li>
<li>Balance sheet 
<ul class="wp-block-list">
<li>~$800 M cash against a ~$400 M annual burn → roughly&nbsp;24&nbsp;months of runway&nbsp;with zero debt.</li>
</ul>
</li>
<li>Risk 
<ul class="wp-block-list">
<li>Biology can always surprise.</li>
<li>FDA hurdles, capital raises if share price pops.</li>
</ul>
</li>
<li>Position sizing 
<ul class="wp-block-list">
<li>Treat as a&nbsp;lotto ticket: less than 1% of portfolio in common shares—small enough to torch without blinking, big enough to matter if the therapy works.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Why I Like The Pair Trade</h3>
<ul class="wp-block-list">
<li>Company&nbsp;A&nbsp;offers steady cash flow, strong technical momentum, and optionality via a low‑cost spread strategy.</li>
<li>Company&nbsp;B&nbsp;is binary, but the upside—an outright cure for T1D—is hard to overstate.</li>
<li>Both should rebound once the MFN headlines fade and investors remember revenue isn't set by social media posts.</li>
</ul>
I have trades&nbsp;teed up&nbsp;for both names. If you'd like to know the tickers and get an alert the moment I pull the trigger, feel free to subscribe to my trading Substack/occasional email list below.&nbsp;
And if you&#8217;d rather limit your risk here, you can download the Portfolio Armor app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg" alt="" class="wp-image-12777" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg" alt="" class="wp-image-12778" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Biotech

Equities

Opinion

Profiting From A Pharma Panic

EverCommerce Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) reported better-than-expected first-quarter sales results, after the <a href="https://www.benzinga.com/quote/evcm/earnings">closing bell on Thursday.</a>
EverCommerce reported quarterly earnings of 1 cent per share which missed the analyst consensus estimate of 3 cents per share. The company reported quarterly sales of $142.27 million which beat the analyst consensus estimate of $139.57 million.
&#8220;EverCommerce&#8217;s first quarter results exceeded the top end of our guidance range for both Revenue and Adjusted EBITDA, driven by strong execution and continued active cost management,&#8221; said Eric Remer, EverCommerce&#8217;s Founder and CEO. &#8220;We continue to make solid progress with implementing our transformation and optimization initiatives, which include strategic investments in high margin areas of business such as payments monetization as well as artificial intelligence.&#8221;
EverCommerce said it sees second-quarter sales of $144.500 million to $147.500 million, versus market estimates of $145.93 million.
EverCommerce shares gained 2.4% to trade at $11.26 on Monday.
These analysts made changes to their price targets on EverCommerce following earnings announcement.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst David Hynes maintained EverCommerce with a Buy and raised the price target from $13 to $14.</li>
<li>Barclays analyst Ryan Macwilliams maintained the stock with an Equal-Weight rating and raised the price target from $9 to $11.</li>
</ul>
Considering buying EVCM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-1024x592.png" alt="" class="wp-image-912140" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

EVCM

EverCommerce Analysts Raise Their Forecasts After Upbeat Sales

RBC Capital analyst Brad Erickson reiterates CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Outperform and maintains $42 price target.

CARG

RBC Capital Reiterates Outperform on CarGurus, Maintains $42 Price Target

Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Sector Perform and raises the price target from $18 to $19.

SBRA

Scotiabank Maintains Sector Perform on Sabra Health Care REIT, Raises Price Target to $19

Inno Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 206.3%

Scotiabank analyst Greg Harrison maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Sector Outperform and lowers the price target from $52 to $51.

Comments

Regional Health Props

Regional Health Props (RHEPB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO